Invivyd, Inc.: Clinical Trials

3 completed, 2 active not recruiting, 2 terminated, 1 not yet recruiting. 5 Phase 3, 3 Phase 2, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	5	Completed 2, Terminated 2, Active not recruiting 1
Phase 2	3	Terminated 2, Not yet recruiting 1
Phase 1	2	Active not recruiting 1, Completed 1

Follow Invivyd, Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome VYD2311, Placebo - Long COVID, COVID-19 (SARS-CoV-2 Infection)	Phase 2	Not yet recruiting	Invivyd, Inc.	130	2026-10-01	2026-10-27
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline) - COVID-19	Phase 3	Completed	Invivyd, Inc.	210	2026-06-08	2026-10-14
Study of VYD2311 for the Prevention of COVID-19 VYD2311-SD, VYD2311-MD, Placebo - COVID-19	Phase 3	Active not recruiting	Invivyd, Inc.	1770	2026-01-08	2026-06-10
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants VYD2311, Placebo - COVID-19	Phase 1	Active not recruiting	Invivyd, Inc.	40	2024-08-28	2024-11-19
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2 VYD222 (pemivibart), Normal saline - COVID-19, SARS-CoV-2	Phase 3	Completed	Invivyd, Inc.	790	2023-09-08	2024-12-09
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants VYD222, Placebo - COVID-19	Phase 1	Completed	Invivyd, Inc.	30	2023-03-28	2024-05-31
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19 ADG20, Normal saline - COVID-19	Phase 2 / Phase 3	Terminated	Invivyd, Inc.	399	2021-07-26	2024-02-06
Evaluation of ADG20 for the Prevention of COVID-19 ADG20, Placebo - COVID-19	Phase 2 / Phase 3	Terminated	Invivyd, Inc.	2582	2021-04-27	2024-08-20
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments VYD222 - COVID-19		No longer available	Invivyd, Inc.			2024-06-03

Conditions studied

COVID-19 (9)  ·  Post-Acute COVID-19 Syndrome (1)

Interventions

Saline Solution (3)  ·  ADG20 (2)  ·  Sodium Chloride (2)  ·  CVnCoV COVID-19 vaccine (1)

Countries

United States (4)  ·  Argentina (2)  ·  Australia (2)  ·  Germany (2)  ·  Moldova (2)  ·  Poland (2)  ·  Romania (2)  ·  Ukraine (2)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Georgia (1)  ·  Greece (1)  ·  Hungary (1)  ·  South Africa (1)

Results publications

PMID 34473343, PMID 42165235, PMID 35713300, PMID 37351456, PMID 37496612, PMID 40410927, PMID 41697535